fulvestrant has been researched along with pyrroles in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 5 (45.45) | 2.80 |
| Authors | Studies |
|---|---|
| Bland, KI; Filardo, EJ; Frackelton, AR; Quinn, JA | 1 |
| Dai, A; Hashimura, K; Komesaroff, PA; Ling, S; Little, PJ; Liu, JP; Sudhir, K; Williams, MR | 1 |
| Alper, RH; Mize, AL | 1 |
| Campbell, H; Davies, BR; Dowsett, M; Gao, Q; Guest, SK; Johnston, S; Liccardi, G; Marangoni, E; Martin, LA; Pancholi, S; Polanska, UM; Rani, A; Ribas, R; Simigdala, N; Thuleau, A | 1 |
| Chandrasekaran, G; Kumar, D; Kumar, T; Mahobiya, A; Parida, S; Rungsung, S; Singh, TU | 1 |
| Alchami, F; Bale, C; Bezecny, P; Butler, R; Carucci, M; Casbard, A; Cox, C; Foxley, A; Howell, SJ; Joffe, J; Jones, RH; Madden, TA; Moon, S; Twelves, C; Venkitaraman, R; Waters, S | 1 |
| Abraham, J; Baird, RD; Bliss, JM; Braybrooke, JP; Bye, H; Cameron, D; Cutts, R; Gevensleben, H; Hubank, M; Kernaghan, S; Kilburn, LS; Kingston, B; Macpherson, IR; Martin, S; Moretti, L; Oikonomidou, O; Randle, K; Rea, D; Ring, A; Roylance, R; Shaaban, A; Snowdon, C; Stephens, P; Turner, NC; Tuthill, M; Wardley, AM; Wilkinson, K; Winter, MC | 1 |
| Andrikopoulou, A; Chatzinikolaou, S; Dimopoulos, MA; Kaparelou, M; Liontos, M; Panourgias, E; Zagouri, F | 1 |
| Bale, C; Bezecny, P; Butler, R; Carucci, M; Casbard, A; de Bruin, EC; Foxley, A; Howell, SJ; Ingarfield, K; Jones, RH; Meissner, M; Moon, S; Morgan, S; Schiavon, G; Twelves, C; Venkitaraman, R; Waters, S | 1 |
1 review(s) available for fulvestrant and pyrroles
| Article | Year |
|---|---|
"The emerging role of capivasertib in breast cancer".
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Mutation; Paclitaxel; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, ErbB-2 | 2022 |
3 trial(s) available for fulvestrant and pyrroles
| Article | Year |
|---|---|
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Double-Blind Method; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fulvestrant; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Pyrimidines; Pyrroles; Receptors, Estrogen; Salvage Therapy; Survival Rate | 2020 |
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.
Topics: Adult; Aged; Biomarkers, Tumor; Breast Neoplasms; Circulating Tumor DNA; Estrogen Receptor alpha; Female; Fulvestrant; Genotype; Humans; Middle Aged; Molecular Targeted Therapy; Mutation; Prospective Studies; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrimidines; Pyrroles; Quinolines; Receptor, ErbB-2; Receptors, Estrogen; Treatment Outcome | 2020 |
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomar
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Female; Fulvestrant; Humans; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Progression-Free Survival; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, ErbB-2; Receptors, Estrogen | 2022 |
7 other study(ies) available for fulvestrant and pyrroles
| Article | Year |
|---|---|
Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis.
Topics: Adenylyl Cyclases; Breast Neoplasms; Carbazoles; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; ErbB Receptors; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Humans; Indoles; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-raf; Pyrroles; Receptors, Cell Surface; Receptors, Estrogen; Receptors, G-Protein-Coupled; Tamoxifen; Tumor Cells, Cultured | 2002 |
High glucose abolishes the antiproliferative effect of 17beta-estradiol in human vascular smooth muscle cells.
Topics: Becaplermin; Blotting, Western; Cell Division; Cells, Cultured; DNA; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Glucose; Humans; Mesylates; Muscle, Smooth, Vascular; Platelet-Derived Growth Factor; Protein Kinase C; Proto-Oncogene Proteins c-sis; Pyrroles | 2002 |
Rapid uncoupling of serotonin-1A receptors in rat hippocampus by 17beta-estradiol in vitro requires protein kinases A and C.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Carbazoles; Cell Membrane; Culture Techniques; Cyclic AMP-Dependent Protein Kinases; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Guanosine 5'-O-(3-Thiotriphosphate); Hippocampus; Indoles; Naphthalenes; Ovariectomy; Phosphorylation; Protein Kinase C; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Staurosporine | 2002 |
AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cluster Analysis; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Female; Fulvestrant; Gene Expression Profiling; Humans; Mice; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Pyrimidines; Pyrroles; Receptors, Estrogen; Signal Transduction; TOR Serine-Threonine Kinases; Transcriptional Activation; Xenograft Model Antitumor Assays | 2015 |
Targeting Mutant AKT in Cancer.
Topics: Clinical Trials, Phase I as Topic; Drug Synergism; Estradiol; Fulvestrant; Humans; Mutation; Neoplasms; Neoplastic Cells, Circulating; Precision Medicine; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Treatment Outcome | 2016 |
Kaempferol-induces vasorelaxation via endothelium-independent pathways in rat isolated pulmonary artery.
Topics: Animals; Apamin; Barium Compounds; Calcium Chloride; Chlorides; Dose-Response Relationship, Drug; Endothelium, Vascular; Estradiol; Fulvestrant; Glyburide; In Vitro Techniques; Indomethacin; Isoquinolines; Kaempferols; Male; Morpholines; NG-Nitroarginine Methyl Ester; Oxadiazoles; Peptides; Potassium; Pulmonary Artery; Pyrroles; Quinoxalines; Rats; Sulfonamides; Tetraethylammonium; Vasodilation; Vasodilator Agents | 2018 |
Capivasertib Doubles PFS in Some Breast Cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Fulvestrant; Humans; Pyrimidines; Pyrroles; Receptor, ErbB-2 | 2023 |